TY  - JOUR
AU  - Topić-Vučenović, Valentina
AU  - Rajkovača, Zvezdana
AU  - Jelić, Dijana
AU  - Stanimirović, Dragi
AU  - Vuleta, Goran
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3207
AB  - Radioiodine (I-131) therapy is the common treatment option for benign thyroid diseases. The objective of this study was to characterize I-131 biokinetics in patients with benign thyroid disease and to investigate and quantify the influence of patients' demographic and clinical characteristics on intra-thyroidal I-131 kinetics by developing a population model. Population pharmacokinetic analysis was performed using a nonlinear mixed effects approach. Data sets of 345 adult patients with benign thyroid disease, retrospectively collected from patients' medical records, were evaluated in the analysis. The two-compartment model of I-131 biokinetics representing the blood compartment and thyroid gland was used as the structural model. Results of the study indicate that the rate constant of the uptake of I-131 into the thyroid (k (tu)) is significantly influenced by clinical diagnosis, age, functional thyroid volume, free thyroxine in plasma (fT(4)), use of anti-thyroid drugs, and time of discontinuation of therapy before administration of the radioiodine (THDT), while the effective half-life of I-131 is affected by the age of the patients. Inclusion of the covariates in the base model resulted in a decrease of the between subject variability for k (tu) from 91 (3.9) to 53.9 (4.5)%. This is the first population model that accounts for the influence of fT(4) and THDT on radioiodine kinetics. The model could be used for further investigations into the correlation between thyroidal exposure to I-131 and the outcome of radioiodine therapy of benign thyroid disease as well as the development of dosing recommendations.
PB  - Springer Heidelberg, Heidelberg
T2  - European Journal of Clinical Pharmacology
T1  - Investigation of factors influencing radioiodine (I-131) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach
VL  - 74
IS  - 8
SP  - 1037
EP  - 1045
DO  - 10.1007/s00228-018-2459-8
ER  - 

@article{
author = "Topić-Vučenović, Valentina and Rajkovača, Zvezdana and Jelić, Dijana and Stanimirović, Dragi and Vuleta, Goran and Miljković, Branislava and Vučićević, Katarina",
year = "2018",
abstract = "Radioiodine (I-131) therapy is the common treatment option for benign thyroid diseases. The objective of this study was to characterize I-131 biokinetics in patients with benign thyroid disease and to investigate and quantify the influence of patients' demographic and clinical characteristics on intra-thyroidal I-131 kinetics by developing a population model. Population pharmacokinetic analysis was performed using a nonlinear mixed effects approach. Data sets of 345 adult patients with benign thyroid disease, retrospectively collected from patients' medical records, were evaluated in the analysis. The two-compartment model of I-131 biokinetics representing the blood compartment and thyroid gland was used as the structural model. Results of the study indicate that the rate constant of the uptake of I-131 into the thyroid (k (tu)) is significantly influenced by clinical diagnosis, age, functional thyroid volume, free thyroxine in plasma (fT(4)), use of anti-thyroid drugs, and time of discontinuation of therapy before administration of the radioiodine (THDT), while the effective half-life of I-131 is affected by the age of the patients. Inclusion of the covariates in the base model resulted in a decrease of the between subject variability for k (tu) from 91 (3.9) to 53.9 (4.5)%. This is the first population model that accounts for the influence of fT(4) and THDT on radioiodine kinetics. The model could be used for further investigations into the correlation between thyroidal exposure to I-131 and the outcome of radioiodine therapy of benign thyroid disease as well as the development of dosing recommendations.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "European Journal of Clinical Pharmacology",
title = "Investigation of factors influencing radioiodine (I-131) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach",
volume = "74",
number = "8",
pages = "1037-1045",
doi = "10.1007/s00228-018-2459-8"
}

Topić-Vučenović, V., Rajkovača, Z., Jelić, D., Stanimirović, D., Vuleta, G., Miljković, B.,& Vučićević, K.. (2018). Investigation of factors influencing radioiodine (I-131) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach. in European Journal of Clinical Pharmacology
Springer Heidelberg, Heidelberg., 74(8), 1037-1045.
https://doi.org/10.1007/s00228-018-2459-8

Topić-Vučenović V, Rajkovača Z, Jelić D, Stanimirović D, Vuleta G, Miljković B, Vučićević K. Investigation of factors influencing radioiodine (I-131) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach. in European Journal of Clinical Pharmacology. 2018;74(8):1037-1045.
doi:10.1007/s00228-018-2459-8 .

Topić-Vučenović, Valentina, Rajkovača, Zvezdana, Jelić, Dijana, Stanimirović, Dragi, Vuleta, Goran, Miljković, Branislava, Vučićević, Katarina, "Investigation of factors influencing radioiodine (I-131) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach" in European Journal of Clinical Pharmacology, 74, no. 8 (2018):1037-1045,
https://doi.org/10.1007/s00228-018-2459-8 . .

TY  - CONF
AU  - Topić-Vučenović, Valentina
AU  - Vučićević, Katarina
AU  - Rajkovača, Zvezdana
AU  - Stanimirović, D.
AU  - Vuleta, Goran
AU  - Jelić, D.
AU  - Miljković, Branislava
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2924
PB  - Springer, New York
C3  - European Journal of Nuclear Medicine and Molecular Imaging
T1  - Investigation of influence of anti-thyroid drug discontinuation time on I-131 biokinetics in patients with benign thyroid disease
VL  - 44
IS  - Supplement 2
SP  - S809
EP  - S809
DO  - 10.1007/s00259-017-3822-1
ER  - 

@conference{
author = "Topić-Vučenović, Valentina and Vučićević, Katarina and Rajkovača, Zvezdana and Stanimirović, D. and Vuleta, Goran and Jelić, D. and Miljković, Branislava",
year = "2017",
publisher = "Springer, New York",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
title = "Investigation of influence of anti-thyroid drug discontinuation time on I-131 biokinetics in patients with benign thyroid disease",
volume = "44",
number = "Supplement 2",
pages = "S809-S809",
doi = "10.1007/s00259-017-3822-1"
}

Topić-Vučenović, V., Vučićević, K., Rajkovača, Z., Stanimirović, D., Vuleta, G., Jelić, D.,& Miljković, B.. (2017). Investigation of influence of anti-thyroid drug discontinuation time on I-131 biokinetics in patients with benign thyroid disease. in European Journal of Nuclear Medicine and Molecular Imaging
Springer, New York., 44(Supplement 2), S809-S809.
https://doi.org/10.1007/s00259-017-3822-1

Topić-Vučenović V, Vučićević K, Rajkovača Z, Stanimirović D, Vuleta G, Jelić D, Miljković B. Investigation of influence of anti-thyroid drug discontinuation time on I-131 biokinetics in patients with benign thyroid disease. in European Journal of Nuclear Medicine and Molecular Imaging. 2017;44(Supplement 2):S809-S809.
doi:10.1007/s00259-017-3822-1 .

Topić-Vučenović, Valentina, Vučićević, Katarina, Rajkovača, Zvezdana, Stanimirović, D., Vuleta, Goran, Jelić, D., Miljković, Branislava, "Investigation of influence of anti-thyroid drug discontinuation time on I-131 biokinetics in patients with benign thyroid disease" in European Journal of Nuclear Medicine and Molecular Imaging, 44, no. Supplement 2 (2017):S809-S809,
https://doi.org/10.1007/s00259-017-3822-1 . .